Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy
The efficacy of oncolytic adenoviruses is limited by strong immune responses being induced against the oncolytic virus itself. Here, the authors generate a bispecific molecule capable of redirecting the adenovirus-specific antibodies to tumour cells and show this induces immune mediated cancer growt...
Guardado en:
Autores principales: | Julia Niemann, Norman Woller, Jennifer Brooks, Bettina Fleischmann-Mundt, Nikolas T. Martin, Arnold Kloos, Sarah Knocke, Amanda M. Ernst, Michael P. Manns, Stefan Kubicka, Thomas C. Wirth, Rita Gerardy-Schahn, Florian Kühnel |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5216df34738f45e49e9168b8b9041417 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.
por: Patrizia Nanni, et al.
Publicado: (2013) -
Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy
por: Masmudur M. Rahman, et al.
Publicado: (2021) -
Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy
por: Huiya Huang, et al.
Publicado: (2019) -
Retargeting Lentiviruses via SpyCatcher-SpyTag Chemistry for Gene Delivery into Specific Cell Types
por: Nagarjun Kasaraneni, et al.
Publicado: (2017) -
Genomic retargeting of p53 and CTCF is associated with transcriptional changes during oncogenic HRas-induced transformation
por: Michal Schwartz, et al.
Publicado: (2020)